151607-70-4

Basic information

• Product Name: Methyl 1-trityl-1H-1,2,4-triazole-3-carboxylate
• Synonyms: Methyl 1-trityl-1H-1,2,4-triazole-3-carboxylate;methyl 1-trityl-1H-1,2,4-triazol-3-carboxylate
• CAS NO: 151607-70-4
• Molecular Formula: C₂₃H₁₉N₃O₂
• Molecular Weight: 369.41586
• Mol File: 151607-70-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 554.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: -0.04±0.50(Predicted)
• CAS DataBase Reference: Methyl 1-trityl-1H-1,2,4-triazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-trityl-1H-1,2,4-triazole-3-carboxylate(151607-70-4)
• EPA Substance Registry System: Methyl 1-trityl-1H-1,2,4-triazole-3-carboxylate(151607-70-4)

Safety Data

• Hazardous Substances Data: 151607-70-4(Hazardous Substances Data)

Upstream product

• 31250-99-4 1-triphenylmethyl-1,2,4-triazole 
• 76-83-5 trityl chloride 
• 4928-88-5 methyl 1H-1,2,4-triazole-3-carboxylate 

Downstream Products

• 163009-16-3 [1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]methyl methanesulfonate 
• 637335-74-1 1-trityl-1H-[1,2,4]triazole-3-carboxylic acid (4-{[6-amino-1-butyl-3-(2-fluoro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-ylcarbamoyl]-methyl}-phenyl)-amide 
• 637335-76-3 1-trityl-1H-[1,2,4]triazole-3-carboxylic acid {4-[3-butyl-1-(2-fluoro-benzyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-ylmethyl]-phenyl}-amide 
• 151607-71-5 3-Hydroxymethyl-1-(triphenylmethyl)-1,2,4-triazole 

Relevant articles and documents

Method for synthesizing 1 - methyl - 1H -1, 2 and 4 - triazol -3 - methyl formate

The invention discloses a synthetic 1 - methyl - 1H -1. The invention discloses a method for 2,4 - triazole -3 - methyl formate and belongs to the technical field of organic synthesis. The reaction of 1,2 and 4 - triazole as a raw material is followed by

SUBSTITUTED NITROGEN CONTAINING COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Discovery of novel, highly potent, and selective matrix metalloproteinase (MMP)-13 inhibitors with a 1,2,4-triazol-3-yl moiety as a zinc binding group using a structure-based design approach

On the basis of a superposition study of X-ray crystal structures of complexes of quinazoline derivative 1 and triazole derivative 2 with matrix metalloproteinase (MMP)-13 catalytic domain, a novel series of fused pyrimidine compounds which possess a 1,2,4-triazol-3-yl group as a zinc binding group (ZBG) was designed. Among the herein described and evaluated compounds, 31f exhibited excellent potency for MMP-13 (IC50 = 0.036 nM) and selectivities (greater than 1,500-fold) over other MMPs (MMP-1, -2, -3, -7, -8, -9, -10, and -14) and tumor necrosis factor-α converting enzyme (TACE). Furthermore, the inhibitor was shown to protect bovine nasal cartilage explants against degradation induced by interleukin-1 and oncostatin M. In this article, we report the discovery of extremely potent, highly selective, and orally bioavailable fused pyrimidine derivatives that possess a 1,2,4-triazol-3-yl group as a novel ZBG for selective MMP-13 inhibition.